Latest Mesalazine Stories

2010-04-14 07:00:00

WALTHAM, Mass., April 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that for the treatment of Crohn's disease, a novel oral drug for the treatment of moderate to severe Crohn's disease would earn 40 percent patient share according surveyed U.S.

2009-07-07 07:00:00

CINCINNATI, July 7 /PRNewswire/ -- Procter & Gamble Pharmaceuticals (P&GP) announced today the availability of Asacol HD (mesalamine) delayed-release tablets, which are indicated for the treatment of moderately active ulcerative colitis (UC), a form of inflammatory bowel disease.

2009-06-04 08:12:45

An electronic diagnostic tool called the SmartPill is swallowed by patients in order to take measurements as it travels through the gastrointestinal tract.

2009-06-01 07:00:00

CHICAGO, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented the results of a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, "Twelve-month Persistence with 5-aminosalicylic Acid Therapy: Results from a Large Pharmacy Database," at Digestive Disease Week, on May 31, 2009.

2009-05-18 09:00:00

MARIETTA, Ga., May 18 /PRNewswire/ -- Ulcerative colitis (UC) is a chronic, inflammatory bowel disease (IBD) affecting half a million people in the United States, yet many patients don't always understand how to recognize or treat the symptoms associated with the disease. Ulcerative colitis is an inflammation of the lining of the rectum and colon.

2009-05-18 08:00:00

Free Medication Provided by Shire to Patients Taking Lialda(R) (mesalamine) or Pentasa(R) (mesalamine) for the Treatment of Ulcerative Colitis Who Have Lost Their Jobs in 2009 PHILADELPHIA, May 18 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, is responding to the needs of patients who are diagnosed with ulcerative colitis (UC) and prescribed gastrointestinal (GI) medications from Shire by expanding its Patient Assistant Program...

2009-03-25 07:00:00

Today's Local Winners Eligible for Consideration in National "Proud to Be GI" Award CINCINNATI, March 25 /PRNewswire/ -- Today, the Society of Gastroenterology Nurses and Associates (SGNA), the premier society representing nursing professionals in gastroenterology and endoscopy, and Procter and Gamble Pharmaceuticals (P&GP), makers of the ulcerative colitis (UC) treatment Asacol(R) (mesalamine) delayed-release tablets, are proud to support "GI Nurses & Associates Day," a day marked...

2009-01-19 11:17:54

Researchers from the Department of Biochemistry and Molecular Biology at the Univesidad de Alcalá (UAH), confirm that N-acetyl-L-cysteine (NAC) combined with mesalamine produces a significant improvement in patients suffering from ulcerative colitis.

2008-11-05 18:00:23

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the third quarter ended September 30, 2008. Total product revenue was $42.9 million for the third quarter of 2008, compared to $67.4 million for the third quarter of 2007.

Word of the Day
  • Large; stout; burly.
The word 'bowerly' is an alteration of 'burly'.